Table 3. Five-years rate of recurrence free survival according to HPV mRNA status of sentinel lymph nodes stratified by tumor size (primary analysis population, n=171).
| Tumor size [mm] | HPV mRNA of SLN | Disease recurrence (n) | 5-years rate of recurrence free survival (95% CI) | |
|---|---|---|---|---|
| all | all | 20 (171) | 90.3 (84.6 – 93.9) % | |
| * | all | negative | 8 (119) | 94.8 (88.8 – 97.6) % |
| positive | 12 (52) | 80.2 (66.2 – 88.8) % | ||
| ** | ≤ 20 | negative | 2 (75) | 98.7 (90.9 – 99.8) % |
| positive | 0 (17) | 100.0 | ||
| >20 to 40 | negative | 3 (30) | 92.6 (73.5 – 98.1) % | |
| positive | 8 (28) | 78.2 (57.8 – 89.6) % | ||
| >40 | negative | 3 (14) | 78.6 (47.2 – 92.5) % | |
| positive | 4 (7) | 42.9 (9.8 – 73.4) % | ||
Abbreviations: SLN – sentinel lymph node, CI – confidence interval
*
Log rank test for HPV mRNA: p = 0.002
**
Log rank test for HPV mRNA adjusted for tumor size: p = 0.027